Latest news
27.01.2020
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections
The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837 in patients with Clostridioides difficile...
22.01.2020
New industrial-scale production of Phyt-N-Resist® to supply the market
DEINOVE launches the production of a new batch of Phyt-N-Resist® to meet the needs of its distributors and future customers. Several...
20.01.2020
DEINOVE announces its financial calendar for 2020
DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...
Press Coverage
19.06.2019
DEINOVE among The Top 20 Industrial Biotechnology Companies in Europe
Europe’s industrial biotechnology sector is driving a massive change from petrochemical processes to more sustainable alternatives. Here...
14.06.2019
Formule Verte | Deinove et Avril avancent sur leur nouvelle gamme d’ingrédients
La société de biotechnologies industrielles Deinove et Avril, l’acteur industriel et financier des filières des huiles et des protéines,...
05.06.2019
Zone Bourse | DEINOVE : LCM confirme sa recommandation d'Achat
LCM a confirmé sa recommandation d'Achat et son objectif de cours de 2,7 euros sur Deinove après la signature d'un partenariat avec Dow...